Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer

Cancer

Volumn 121, Issue 15, 2015, Pages 2603-2611

  McKay, Rana R ^a   Gray, Kathryn P ^a   Hayes, Julia H ^a   Bubley, Glenn J ^b   Rosenberg, Jonathan E ^c   Hussain, Arif ^d   Kantoff, Philip W ^a   Taplin, Mary Ellen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

androgen deprivation therapy; bevacizumab; biochemical disease recurrence; docetaxel; prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BEVACIZUMAB; DOCETAXEL; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; TAXOID; TUMOR MARKER;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BLOOD; CLINICAL TRIAL; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84937515729     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29398     Document Type: Article

References (16)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Novara G, Ficarra V, Mocellin S, et al., Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol. 2012; 62: 382-404.
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC,. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281: 1591-1597.
4. Antonarakis ES, Feng Z, Trock BJ, et al., The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int. 2012; 109: 32-39.
5. Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA,. Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am. 2013; 27: 1205-1219.
6. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR,. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008; 112: 307-314.
7. Kirkwood JM, Tarhini A, Sparano JA, et al., Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. Cancer Treat Rev. 2013; 39: 27-43.
8. Sweeney C, Chen YH, Carducci MA, et al., Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial. ASCO Meeting Abstracts. 2014; 32 (suppl 18): LBA2.
9. Taplin ME, Xie W, Bubley GJ, et al., Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol. 2006; 24: 5408-5413.
10. Nakabayashi M, Xie W, Buckle G, et al., Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013; 81: 611-616.
11. Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D,. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clin Cancer Res. 2004; 10: 8728-8734.
12. Kelly WK, Halabi S, Carducci M, et al., Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012; 30: 1534-1540.
13. Ross RW, Galsky MD, Febbo P, et al., Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012; 118: 4777-4784.
14. Hussain A, Dawson N, Amin P, et al., Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol. 2005; 23: 2789-2796.
15. Schweizer MT, Huang P, Kattan MW, et al., Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. Cancer. 2013; 119: 3610-3618.
16. Crook JM, O'Callaghan CJ, Duncan G, et al., Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012; 367: 895-903.